Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide.

Autor: Goel U; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA., Charalampous C; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Fonder A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves WI; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hobbs MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hwa YL; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame RM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Kumar.Shaji@mayo.edu.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2024 Mar 26; Vol. 14 (1), pp. 55. Date of Electronic Publication: 2024 Mar 26.
DOI: 10.1038/s41408-024-01039-1
Abstrakt: Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment. For second line therapy, we found no difference in the PFS between standard dose refractory and low dose refractory groups (median PFS 14 months vs 14 months, p = 0.95), while the PFS for both these groups was inferior to the not refractory group (median PFS 30 months, p < 0.001 for both pairs). Similar trends were seen among these groups on lenalidomide retreatment, and on multivariable analysis. These data suggest that refractoriness to lenalidomide is not dose dependent, and definition of lenalidomide refractoriness should not depend on the dose of lenalidomide to which the disease was considered refractory.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: